Wall Street Zen Upgrades Treace Medical Concepts (NASDAQ:TMCI) to Sell

Treace Medical Concepts (NASDAQ:TMCI) was upgraded by equities researchers at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research note issued to investors on Saturday.

Other analysts have also recently issued research reports about the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Treace Medical Concepts in a research note on Wednesday, January 21st. Truist Financial cut their target price on shares of Treace Medical Concepts from $4.00 to $3.00 and set a “hold” rating for the company in a research note on Thursday, December 18th. Stifel Nicolaus cut their target price on shares of Treace Medical Concepts from $5.00 to $3.00 and set a “hold” rating for the company in a research note on Wednesday, January 7th. Finally, Lake Street Capital cut their target price on shares of Treace Medical Concepts from $7.50 to $7.00 and set a “buy” rating for the company in a research note on Monday, March 2nd. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus price target of $4.77.

Treace Medical Concepts Stock Performance

Shares of TMCI opened at $1.81 on Friday. The firm has a 50-day moving average of $1.65 and a 200-day moving average of $3.22. Treace Medical Concepts has a one year low of $1.17 and a one year high of $7.78. The company has a market cap of $117.25 million, a PE ratio of -1.93 and a beta of 0.87. The company has a debt-to-equity ratio of 0.64, a current ratio of 4.31 and a quick ratio of 3.13.

Treace Medical Concepts (NASDAQ:TMCI) last announced its quarterly earnings data on Friday, February 27th. The company reported ($0.15) EPS for the quarter, meeting analysts’ consensus estimates of ($0.15). The company had revenue of $62.52 million during the quarter, compared to the consensus estimate of $61.76 million. Treace Medical Concepts had a negative net margin of 27.74% and a negative return on equity of 59.91%. As a group, equities analysts forecast that Treace Medical Concepts will post -0.92 earnings per share for the current year.

Institutional Trading of Treace Medical Concepts

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Hsbc Holdings PLC acquired a new stake in Treace Medical Concepts in the 4th quarter worth about $60,000. Caitong International Asset Management Co. Ltd acquired a new stake in Treace Medical Concepts in the 4th quarter worth about $140,000. Aristides Capital LLC acquired a new stake in Treace Medical Concepts in the 4th quarter worth about $173,000. XTX Topco Ltd acquired a new stake in Treace Medical Concepts in the 4th quarter worth about $180,000. Finally, Quadrature Capital Ltd acquired a new stake in Treace Medical Concepts in the 4th quarter worth about $149,000. Institutional investors and hedge funds own 84.08% of the company’s stock.

Treace Medical Concepts Company Profile

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.